Clinical trial
Safety/Efficacy Study of Immunoconjugate With Docetaxel in Non-small Cell Lung…
NCT00051571 · Seagen Inc., Industry · Completed
Key facts
| NCT number | NCT00051571 |
|---|---|
| Title | Safety/Efficacy Study of Immunoconjugate With Docetaxel in Non-small Cell Lung Carcinoma |
| Official title | A Phase II Study Using SGN-15 (cBR96-Doxorubicin Immunoconjugate) in Combination With Docetaxel for the Treatment of Advanced Stage or Recurrent Non-Small Cell Lung Carcinoma |
| Lead sponsor | Seagen Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention type | Drug |
| Interventions | SGN-15, Docetaxel |
| Enrollment | 60 |
| Completion | Oct 1, 2003 |
| First posted | Jan 15, 2003 |
| Last update posted | Oct 24, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: